Clinical Trial Update: PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bendamustine and ofatumumab in relapsed/refractory chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Arzerra (ofatumumab)
• Treanda (Bendamustine)

Snippet

Sponsor: Nevada Cancer Institute | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: WITHDRAWN